Cargando…

Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study

OBJECTIVE: To report the efficacy, long-term safety, and tolerability of using a small dose (125 mg/m2 weekly for 4 weeks) of rituximab to treat Chinese patients with thyroid-associated ophthalmopathy (TAO). METHODS: Seven patients with active moderate-to-severe TAO were prospectively recruited in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yueyue, Hu, Hao, Chen, Lu, Zhang, Haitao, Yang, Tao, Xu, Xiaoquan, Chen, Huanhuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889535/ https://www.ncbi.nlm.nih.gov/pubmed/36743915 http://dx.doi.org/10.3389/fendo.2022.1079852

Ejemplares similares

Comprehensive analysis of key genes and pathways for biological and clinical implications in thyroid-associated ophthalmopathy
por: Wang, Yueyue, et al.
Publicado: (2022)

Treating Thyroid Associated Ophthalmopathy in Pediatric Patients
por: Dong, Tianyu, et al.
Publicado: (2022)

Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy
por: Smith, Terry J.
Publicado: (2020)

Use of Rituximab After Orbital Decompression Surgery in Two Grave’s Ophthalmopathy Patients Progressing to Optic Neuropathy
por: Zhang, Benping, et al.
Publicado: (2020)

Integrative metabolic analysis of orbital adipose/connective tissue in patients with thyroid-associated ophthalmopathy
por: Huang, Jiancheng, et al.
Publicado: (2022)

Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients
por: Li, Lan-Fang, et al.
Publicado: (2023)

Increased brain iron in patients with thyroid-associated ophthalmopathy: a whole-brain analysis
por: Hu, Hao, et al.
Publicado: (2023)

Long-term follow-up of seven patients with ophthalmopathy not associated with thyroid autoimmunity: heterogeneity of autoimmune ophthalmopathy
por: McCorquodale, Tom, et al.
Publicado: (2012)

Current insights of applying MRI in Graves’ ophthalmopathy
por: Song, Cheng, et al.
Publicado: (2022)

Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy
por: Smith, Terry J., et al.
Publicado: (2017)

Rare Co-occurrence of Ocular Myasthenia Gravis and Thyroid-Associated Orbitopathy (Ophthalmopathy) in an Individual With Hypothyroidism
por: An, Ran, et al.
Publicado: (2019)

IL-11 Is Elevated and Drives the Profibrotic Phenotype Transition of Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy
por: Wu, Pengsen, et al.
Publicado: (2022)

Identification of optimal feature genes in patients with thyroid associated ophthalmopathy and their relationship with immune infiltration: a bioinformatics analysis
por: Xiong, Chao, et al.
Publicado: (2023)

Multi-Parametric Diffusion Tensor Imaging of The Optic Nerve for Detection of Dysthyroid Optic Neuropathy in Patients With Thyroid-Associated Ophthalmopathy
por: Liu, Ping, et al.
Publicado: (2022)

Alterations in Spontaneous Neuronal Activity and Microvascular Density of the Optic Nerve Head in Active Thyroid-Associated Ophthalmopathy
por: Zhu, Pingyi, et al.
Publicado: (2022)

Decreased macular choriocapillaris in thyroid-associated ophthalmopathy: focusing on chorioretinal folds with and without optic disc edema
por: Zeng, Peng, et al.
Publicado: (2023)

Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy
por: Fallahi, Poupak, et al.
Publicado: (2021)

Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?
por: Liu, Ping, et al.
Publicado: (2021)

Bisphosphonate-Induced Acute Orbital Inflammation in a Patient With Underlying Thyroid Ophthalmopathy
por: Yu, James, et al.
Publicado: (2020)

Thyroid-associated Ophthalmopathy
por: Şahlı, Esra, et al.
Publicado: (2017)

An Interesting Case of Euthyroid Graves’ Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies
por: Moeen, Zunera, et al.
Publicado: (2021)

Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves’ Ophthalmopathy
por: Wang, Yan, et al.
Publicado: (2022)

Rituximab therapy in steroid-resistant severe hypothyroid Grave's ophthalmopathy
por: Pandit, Aditi, et al.
Publicado: (2013)

Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases
por: Li, Qian, et al.
Publicado: (2017)

Severe Grave's Ophthalmopathy–missed for many years
por: Wani, Mohd Maqbool, et al.
Publicado: (2010)

Altered Corneal Nerves in Chinese Thyroid-Associated Ophthalmopathy Patients Observed by In Vivo Confocal Microscopy
por: Wu, Lian-Qun, et al.
Publicado: (2019)

Cytokines in Thyroid-Associated Ophthalmopathy
por: Zhang, Pengbo, et al.
Publicado: (2022)

Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
por: Le Moli, Rosario, et al.
Publicado: (2020)

Association of variant on the promoter of cluster of differentiation 74 in graves disease and graves ophthalmopathy
por: Liu, Yu-Huei, et al.
Publicado: (2020)

Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves’ Ophthalmopathy
por: Virakul, Sita, et al.
Publicado: (2021)

Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis
por: Wang, Changjun, et al.
Publicado: (2018)

Graves’ Ophthalmopathy in the Setting of Primary Hypothyroidism
por: Alajmi, Sarah, et al.
Publicado: (2022)

Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves’ Ophthalmopathy by Targeting Orbital Fibroblasts
por: Yang, Shenglan, et al.
Publicado: (2022)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Microarray Data of Lacrimal Gland Implicates Dysregulated Protein Processing in Endoplasmic Reticulum in Graves’ Ophthalmopathy
por: Tu, Wenling, et al.
Publicado: (2021)

Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ophthalmopathy: a systematic review and meta-analysis
por: Hu, Yu, et al.
Publicado: (2023)

Mutational profiling of Chinese patients with thyroid cancer
por: Du, Yaying, et al.
Publicado: (2023)

The Combination of Sonographic Features and the Seven-Gene Panel May be Useful in the Management of Thyroid Nodules With Indeterminate Cytology
por: Capezzone, Marco, et al.
Publicado: (2021)

Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves’ Ophthalmopathy to Parenteral Corticosteroids
por: Naselli, Adriano, et al.
Publicado: (2020)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
por: Chen, Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aih047c16lajfv2f49iju13nn7